系统疗法与中期肝细胞癌的局部区域疗法相结合
1Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan.
概括
系统性疗法,如伦瓦提尼布和阿特佐利祖马布加贝瓦西祖马布,对晚期肝细胞癌有很大的前景. 连续的伦瓦提尼布 - 跨动脉化学栓塞和组合免疫疗法改善了生存率和反应率.
科学领域:
- 肝胆道医学 肝胆道医学
- 医学瘤学 医学瘤学
- 翻译研究是翻译研究.
背景情况:
- 肝细胞癌 (HCC) 治疗进展显著.
- 目标各不相同:在晚期延长生存,在中期实现治愈.
- 系统疗法为无法接受跨动脉化学栓塞 (TACE) 的患者提供了替代方案.
研究的目的:
- 评估对中期HCC的顺序列列林瓦提尼布-TACE治疗.
- 为了评估阿特佐利祖马布加贝瓦齐祖马布在高血压病患者的疗效,超过多达七个标准.
- 探索阿特佐利祖马布,贝瓦齐祖马布和中期HCC治愈疗法的组合.
主要方法:
- TACTICS-L试验:可能的第二阶段,伦瓦提尼布-TACE顺序治疗.
- 替代试验:多中心,前性,单臂II期,阿特佐利祖马布加贝瓦西祖马布.
- 概念验证研究:阿特佐利祖马布,贝瓦齐祖马布,加上治愈疗法.
主要成果:
- TACTICS-L 显示,随着 lenvatinib-TACE 的使用,改善了无进展和整体存活率.
- 替代品在特定的HCC人群中证实了阿特佐利祖马布加贝瓦齐祖马布的疗效.
- 概念验证研究报告了35%的完整反应和23%的无毒状态.
结论:
- 序列列宁瓦替尼-TACE是中期HCC的可行选择.
- 组合免疫疗法 (阿特佐利祖马布加贝瓦齐祖马布) 对超过多达七个标准的HCC有效.
- 阿特佐利祖马布,贝瓦齐祖马布和治愈疗法显示出在中期HCC中实现完全和无药状态的潜力.
相关概念视频
01:27Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K